References
- Green JS, O’Brien TJ, Chiappinelli VA, Harralson AF. Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine. Pharmacogenomics 2010; 11:1331–1340.
- Hudson KL. Genomics, health care, and society. N Engl J Med 2011; 365:1033–1041.
- Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010; 105:991–1002.
- Ito H, Yeo KK, Wijetunga M, Seto TB, Tay K, Schatz IJ. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol 2009; 32:E18–E22.
- Willers ED, Newman JH. New risks for pulmonary hypertension: need for a large epidemiologic study. Chest 2006; 130:1633–1635.
- Shetty V, Mooney LJ, Zigler CM, Belin TR, Murphy D, Rawson R. The relationship between methamphetamine use and increased dental disease. J Am Dent Assoc 2010; 141:307–318.
- Li L, Everhart T, Jacob Iii P, Jones R, Mendelson J. Stereoselectivity in the human metabolism of methamphetamine. Br J Clin Pharmacol 2010; 69:187–192.
- Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, et al.; ADHERE Scientific Advisory Committee and Investigators. Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 2008; 102:1216–1219.
- Karch SB. The unique histology of methamphetamine cardiomyopathy: a case report. Forensic Sci Int 2011; 212:e1–e4.
- Cherner M, Bousman C, Everall I, Barron D, Letendre S, Vaida F, et al.; HNRC Group. Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings. J Int Neuropsychol Soc 2010; 16:890–901.
- Cherner M, Suarez P, Casey C, Deiss R, Letendre S, Marcotte T, et al.; HNRC Group. Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend 2010; 106:154–163.
- Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug metabolism and disposition: the biological fate of chemicals 2006; 34:563–569.
- Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007; 81:242–251.
- Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83:234–242.
- Gaedigk A, Jaime LK, Bertino JS Jr, Berard A, Pratt VM, Bradfordand LD, Leeder JS. Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front Pharmacol 2010; 1:121.
- Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med 1999; 170:198–202.
- Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6–13.
- Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352:2211–2221.
- Srikanth S, Barua R, Ambrose J. Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology 2008; 109:188–192.
- Jacobs LJ. Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol 1989; 12:725–727.
- Lopez JE, Yeo K, Caputo G, Buonocore M, Schaefer S. Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2009; 11:46.